好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Wada Test Using Etomidate: Single Center Experience
Epilepsy/Clinical Neurophysiology (EEG)
P3 - Poster Session 3 (5:00 PM-6:00 PM)
11-004
To describe our institutional experience using etomidate for the Wada test in adults with medically refractory epilepsy undergoing presurgical evaluation.
The Wada test remains a key diagnostic tool for assessing memory and language lateralization in epilepsy surgery. While sodium amobarbital has been the traditional agent of choice, global shortages and regulatory issues have prompted evaluation of alternatives such as methohexital, pentobarbital, propofol, and etomidate.
We conducted a single-center retrospective review of consecutive patients aged >18 years who underwent Wada testing at our institution between January 2024 and July 2025. Clinical records were reviewed, and demographic as well as procedural covariates were extracted. During each Wada test, 16 items (8 visual and 8 verbal) were presented for memory assessment. Descriptive statistical analyses were performed to summarize patient characteristics and test outcomes.

Nine patients with English as their primary language were included. Of these, 6 were female, and 7 were White. Seizure focus was localized to the left temporal lobe in 7 patients and to the right in 2, as identified by video- EEG. None had a history of prior epilepsy surgery. Mean baseline memory score was 13 ± 1.94. 

A total of 18 etomidate injections were administered, one per hemisphere, at doses of 1 mg (7/9) and 2 mg (2/9). Loss of motor power occurred within 13 ± 5.7 seconds after the injection, and recovery was achieved in 277.5 ± 93.5 seconds. The interval between the final item presentation and recovery averaged 262.9 ± 140.5 seconds (Mean ± SD). None required repeat dosing, and no seizures, stroke, or bleeding complications were observed. 

Our findings support etomidate as a reasonable alternative during the Wada test, given its rapid onset, quick recovery time, effective single-dose administration, and lack of complications.

Authors/Disclosures
Muhammad Khalid, MD (LSU shreveport)
PRESENTER
Dr. Khalid has nothing to disclose.
Bhrugun Anisetti, MBBS Dr. Anisetti has nothing to disclose.
Mohamed M. Ali, MD (LSUHS) Dr. Ali has nothing to disclose.
Rahul Shah, MBBS (LSU Shreveport) Dr. Shah has nothing to disclose.
Amey Savardekar (LSU Shreveport) No disclosure on file
Roohi Katyal, MD (Louisiana State University Health Sciences Center) Dr. Katyal has nothing to disclose.
Christina Ledbetter, PhD Dr. Ledbetter has nothing to disclose.
Mostafa Hotait, MD Dr. Hotait has nothing to disclose.